Interview of Dr. Jin-San Yoo, CEO of PharmAbcine with informa

"PharmAbcine's Hopes Rise As Tanibirumab Set For Keytruda Combo Trials"



PharmAbcine CEO Jin-San Yoo talks to Scrip about the company’s overseas clinical trial strategy, pipeline assets, and ambitions for lead candidate TTAC-0001, which the company sees as superior to Avastin. The Korean biotech, which is engaged in various global collaborations on its investigative antibody drugs, hopes that tie-ups can lead to bigger outcomes going forward.

 Please check  PDF file for details.